Open Labeled Study Of Imatinib Mesylate (Gleevec) In The Treatment Of Systemic Sclerosis- Associated Active Interstitial Lung Disease (SSc-ILD): Preliminary Results

2010 ◽  
Author(s):  
Rajeev Saggar ◽  
Dinesh Khanna ◽  
Maureen D. Mayes ◽  
Philip Clements ◽  
Paul Maranian ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Imatinib Mesylate ◽  
Preliminary Results

scholarly journals A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

2011 ◽  
Vol 63 (11) ◽  
pp. 3540-3546 ◽  
Author(s):  
Dinesh Khanna ◽  
Rajeev Saggar ◽  
Maureen D. Mayes ◽  
Fereidoun Abtin ◽  
Philip J. Clements ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Phase I ◽  
Lung Disease ◽  
Imatinib Mesylate ◽  
Pilot Trial ◽  
Open Label ◽  
One Year

scholarly journals Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease

2019 ◽  
Vol 15 (10) ◽  
pp. 1009-1017 ◽  
Author(s):  
Oliver Distler ◽  
Elizabeth R. Volkmann ◽  
Anna Maria Hoffmann-Vold ◽  
Toby M. Maher
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Future Perspectives

scholarly journals Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

2019 ◽  
Vol 380 (26) ◽  
pp. 2518-2528 ◽  
Author(s):  
Oliver Distler ◽  
Kristin B. Highland ◽  
Martina Gahlemann ◽  
Arata Azuma ◽  
Aryeh Fischer ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease
Sign in / Sign up

Export Citation Format

Share Document